Summary of COVID-19 edaravone studies

1. Moslemi et al., Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial

38 patient edaravone ICU RCT: 75% lower ventilation (p=0.06) and 10% longer ICU admission (p=0.92).
RCT 38 severe COVID-19 ICU patients showing lower need for endotracheal intubation, but no significant difference in mortality with edaravone.
Jun 2022, Inflammopharmacology, https://link.springer.com/10.1007/s10787-022-01001-2, https://c19p.org/moslemi